...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nephron >Limitations of Standard Immunosuppressiwe Treatment in ANCA-Associated Vasculitis and Lupus Nephritis
【24h】

Limitations of Standard Immunosuppressiwe Treatment in ANCA-Associated Vasculitis and Lupus Nephritis

机译：ANCA相关性血管炎和狼疮性肾炎的标准免疫抑制治疗的局限性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction of the standard immunosuppressive treatment has dramatically changed the outcome of patients with both ANCA-associated vasculitis and lupus nephritis, transforming them from incurable diseases with very high short-term mortality to chronic debilitating diseases with much lower short-term, but still relatively high long-term, morbidity/ mortality. Long-term morbidity with damage accumulating partly due to the adverse events of the available treatment (namely gonadal toxicity, malignancy, bone disease, cataracts, diabetes, and thromboembolic and cardiovascular disease) has become a major concern. Although cyclophos-phamide-based regimens have been partly replaced by newer agents in both ANCA-associated vasculitis and lupus nephritis (namely rituximab or mycophenolate, respectively) their short-term and medium-term adverse events may not be significantly less frequent and we can only hope that new treatments will translate into better long-term outcomes including better long-term safety.
机译：引入标准的免疫抑制疗法已极大地改变了ANCA相关性血管炎和狼疮性肾炎患者的预后，将其从短期死亡率很高的无法治愈的疾病转变为短期死亡率较低但仍相对较高的慢性衰弱性疾病长期的，发病率/死亡率。部分由于现有治疗的不良事件（即性腺毒性，恶性肿瘤，骨病，白内障，糖尿病以及血栓栓塞性和心血管性疾病）引起的长期发病率和损害累积已成为主要问题。尽管在ANCA相关的血管炎和狼疮性肾炎（分别为利妥昔单抗或霉酚酸酯）中，以环磷酰胺为基础的治疗方案已部分被新型药物替代，但其短期和中期不良事件的发生频率可能​​不会明显降低，我们可以只希望新疗法能带来更好的长期结果，包括更好的长期安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号